TRCT
MDCX

Tower Research Capital (TRC)’s Medicus Pharma MDCX Stock Holding History

Tower Research Capital (TRC)’s Portfolio MDCX Stock Details MDCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$56 Buy
+121
New +$126 ﹤0.01% 5029

Other funds holding MDCX

ICP
Interchange Capital Partners Pittsburgh, Pennsylvania $532M AUM 26.57% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.48B AUM 24.77% 1-Year Est. Return
MHC
May Hill Capital Cohasset, Massachusetts $398M AUM 23.9% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Tower Research Capital (TRC)'s MDCX Position: Q1 2026 in Review

Tower Research Capital (TRC) opened a new position in Medicus Pharma (MDCX) in Q1 2026: 121 shares worth $56. The stake represents ﹤0.01% of the portfolio and ranks #5029 among its holdings.

21 funds tracked by Wall St. Rank hold MDCX as of Q1 2026.

  • Tower Research Capital (TRC) held 121 shares of Medicus Pharma worth $56 as of Q1 2026.
  • Medicus Pharma was a new Tower Research Capital (TRC) position in Q1 2026.
  • Medicus Pharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #5029 holding.
  • 21 funds tracked by Wall St. Rank held Medicus Pharma as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.